Crossover from stationary to aging regime in glassy dynamics

We study the non-equilibrium dynamics of the spherical p-spin models in the scaling regime near the plateau and derive the corresponding scaling functions for the correlators. Our main result is that the matching between different time regimes fixes the aging function in the aging regime to $h(t)=\exp(t^{1-\mu})$. The exponent $\mu$ is related to the one giving the length of the plateau. Interestingly $1-\mu$ is quickly very small when one goes away from the dynamic transition temperature in the glassy phase. This gives new light on the interpretation of experiments and simulations where simple aging was found to be a reasonable but not perfect approximation, which could be attributed to the existence of a small but non-zero stretching exponent.Comment: 7 pages+2 figure

A Crash Course on Aging

In these lecture notes I describe some of the main theoretical ideas emerged to explain the aging dynamics. This is meant to be a very short introduction to aging dynamics and no previous knowledge is assumed. I will go through simple examples that allow one to grasp the main results and predictions.Comment: Lecture Notes (22 pages) given at "Unifying Concepts in Glass Physics III", Bangalore (2004); to be published in JSTA

Slow dynamics and aging in spin-glasses

Contribution presented by Eric Vincent in the Conference `Complex Behaviour of Glassy Systems', Sitges, Barcelona, Spain, June, 1996. It contains a review of the experimental results on Slow dynamics and aging in spin-glasses. It also presents their comparison with recent theoretical developments in the description of the out of equilibrium dynamics of disordered systems; namely, the trap model and the mean-field theory.Comment: 35 pages, 12 figures, macro lmamult.sty (included

Extended droplet theory for aging in short-ranged spin glasses and a numerical examination

We analyze isothermal aging of a four dimensional Edwards-Anderson model in detail by Monte Carlo simulations. We analyze the data in the view of an extended version of the droplet theory proposed recently (cond-mat/0202110) which is based on the original droplet theory plus conjectures on the anomalously soft droplets in the presence of domain walls. We found that the scaling laws including some fundamental predictions of the original droplet theory explain well our results. The results of our simulation strongly suggest the separation of the breaking of the time translational invariance and the fluctuation dissipation theorem in agreement with our scenario.Comment: 27 pages, 39 epsfiles, revised versio

Non-Fermi-Liquid Scaling in Ce(Ru_{0.5}Rh_{0.5})_2Si_2

We study the temperature and field dependence of the magnetic and transport properties of the non-Fermi-liquid compound Ce(Ru_{1-x}Rh_x)_2Si_2 at x=0.5. For fields $\lesssim$0.1T the experimental results show signatures of the presence of Kondo-disorder, expected to be large at this concentration. For larger fields, however, magnetic and transport properties are controlled by the coupling of the conduction electrons to critical spin-fluctuations. The temperature dependence of the susceptibility as well as the scaling properties of the magnetoresistance are in very good agreement with the predictions of recent dynamical mean-field theories of Kondo alloys close to a spin-glass quantum critical point.Comment: 4 pages, 4 figures. Improved discussion. To appear in Phys. Rev. Let

Non-linear sigma model study of magnetic dephasing in a mesoscopic spin glass

We propose a nonlinear sigma model for the description of quantum transport in a mesoscopic metallic conductor with magnetic impurities frozen in a spin glass phase. It accounts for the presence of both the corresponding scalar and magnetic random potentials. In a spin glass, this magnetic random potential is correlated between different realizations. As the strength of the magnetic potential is varied, this model describes the crossover between orthogonal and unitary universality classes of the nonlinear sigma model. We apply this technique to the calculations of the correlation of conductance between two frozen spin configurations in terms of dephasing rates for the usual low energy modes of weak localization theory.Comment: 6 pages, 2 figure

Thermopower in the strongly overdoped region of single-layer Bi2Sr2CuO6+d superconductor

The evolution of the thermoelectric power S(T) with doping, p, of single-layer Bi2Sr2CuO6+d ceramics in the strongly overdoped region is studied in detail. Analysis in term of drag and diffusion contributions indicates a departure of the diffusion from the T-linear metallic behavior. This effect is increased in the strongly overdoped range (p~0.2-0.28) and should reflect the proximity of some topological change.Comment: 4 pages, 4 figure

Observation of Fluctuation-Dissipation-Theorem Violations in a Structural Glass

The fluctuation-dissipation theorem (FDT), connecting dielectric susceptibility and polarization noise was studied in glycerol below its glass transition temperature Tg. Weak FDT violations were observed after a quench from just above to just below Tg, for frequencies above the alpha peak. Violations persisted up to 10^5 times the thermal equilibration time of the configurational degrees of freedom under study, but comparable to the average relaxation time of the material. These results suggest that excess energy flows from slower to faster relaxing modes.Comment: Improved discussion; final version to appear in Phys. Rev. Lett. 4 pages, 5 PS figures, RevTe

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.

CD38 is a transmembrane glycoprotein that functions both as a receptor and an ectoenzyme, playing key roles in the regulation of calcium signaling and migration of immune cells to tumor microenvironments. High expression on multiple myeloma (MM) cells and limited expression on normal cells makes CD38 an ideal target for the treatment of MM patients. Two monoclonal antibodies directed at CD38, isatuximab and daratumumab, are available for use in patients with relapsed and/or refractory MM (RRMM); daratumumab is also approved in newly diagnosed MM and light-chain amyloidosis. Clinical experience has shown that anti-CD38 antibody therapy is transforming treatment of MM owing to its anti-myeloma efficacy and manageable safety profile. Isatuximab and daratumumab possess similarities and differences in their mechanisms of action, likely imparted by their binding to distinct, non-overlapping epitopes on the CD38 molecule. In this review, we present the mechanistic properties of these two antibodies and outline available evidence on their abilities to induce adaptive immune responses and modulate the bone marrow niche in MM. Further, we discuss differences in regulatory labeling between these two agents and analyze recent key clinical trial results, including evidence in patients with underlying renal impairment and other poor prognostic factors. Finally, we describe the limited existing evidence for the use of isatuximab or daratumumab after disease progression on prior anti-CD38 mono- or combination therapy, highlighting the need for additional clinical evaluations to define optimal anti-CD38 antibody therapy selection and sequencing in RRMM